Novartis, Paratek in deal to develop MRSA drug

10/8/2009 | Reuters

Novartis acquired exclusive global rights to PTK 0796, Paratek Pharmaceuticals' treatment for methicillin-resistant Staphylococcus aureus and other drug-resistant bacteria. The drug is in Phase III trials and has shown promise in safety and tolerability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI